iremycin has been researched along with piritrexim in 1 studies
| Studies (iremycin) | Trials (iremycin) | Recent Studies (post-2010) (iremycin) | Studies (piritrexim) | Trials (piritrexim) | Recent Studies (post-2010) (piritrexim) |
|---|---|---|---|---|---|
| 10 | 0 | 0 | 124 | 21 | 6 |
| Protein | Taxonomy | iremycin (IC50) | piritrexim (IC50) |
|---|---|---|---|
| Dihydrofolate reductase | Mycobacterium avium | 0.0006 | |
| Dihydrofolate reductase | Homo sapiens (human) | 0.0024 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.0015 | |
| Dihydrofolate reductase | Saccharomyces cerevisiae S288C | 0.031 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.0244 | |
| Dipeptidyl peptidase 4 | Rattus norvegicus (Norway rat) | 0.011 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.038 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.0257 | |
| Aromatic-L-amino-acid decarboxylase | Homo sapiens (human) | 0.0006 | |
| Dihydrofolate reductase | Candida albicans | 0.04 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.014 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0091 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0043 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.0134 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 0.0031 | |
| Dihydrofolate reductase | Pneumocystis jirovecii | 0.041 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
1 other study(ies) available for iremycin and piritrexim
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |